GERON CORPORATION reports a Return on Equity (ROE) of -30.37%.

What is GERN's dividend yield?

GERON CORPORATION offers a dividend yield of 0.00%.

What is GERN's Quality Score?

Our AI rates GERN's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy GERN?

Our AI Timing Score for GERN is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does GERN belong to?

GERON CORPORATION is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

GERN (NASDAQ) Stock Analysis | GERON CORPORATION

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

GERN AI Analysis Summary

Our AI summary for GERN: GERON CORPORATION (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -30.37%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

GERN

GERON CORPORATION

US:NASDAQ STOCK Healthcare >> Biotechnology News 91

USD 1.29

-0.05 (-3.73%) Day Change

Watchlist Portfolio Compare Chart

0.61

D/E

-30.4%

ROE

-13.0%

ROA

0.00%

Div Yield

GERON CORPORATION
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.29 Price -0.05 (-3.73%) Day Change	NEWS SCORE: 91

GERN, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	91
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.29
PBV / Sector	3.75 / 5.20
Earning Per Share	-0.10

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	12.48 M GREAT
Average 1W Daily Value	15.87 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-35.48 / 98.71
NPM Average (%) / Sector	-20,361.70 / -1,721.76
NPM Change Average (%) / Sector	5.81 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-13.03 / 27.02
ROA Average (%) / Sector	-35.73 / -368.17
ROA Change Average (%) / Sector	-34.13 / 5,404.12
ROE (%) / Sector	-30.37 / 3.47
ROE Average (%) / Sector	-76.45 / 6.51
ROE Change Average (%) / Sector	-33.33 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:54
Symbol	GERN
Name	GERON CORPORATION
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	641.52 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	859.64 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404

Phone: 650 473 7700

Website: https://www.geron.com

Employees: 258

Sector: Healthcare >> Biotechnology

Description: Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.